NOW… You can Dance if You Want to

June 25, 2018 1:45pm

Eric W. Dittmann
Paul Hastings LLP (New York, NY)

Chuck Klein
Co-chair, Intellectual Property Practice
Winston & Strawn LLP (Washington, DC)

Christopher Loh
Fitzpatrick, Cella, Harper & Scinto (New York, NY)

Nicholas Mitrokostas
Partner, IP Litigation
Goodwin Procter LLP (Boston, MA)

Rachel Moodie
Vice President Intellectual Property, Biosimilars
Fresenius Kabi SwissBioSim GmbH (Aubonne, CH)


Laurie Hill
Vice President of Intellectual Property
Genentech (South San Francisco, CA)

Now that one year has passed since Sandoz v. Amgen, the biologics industry still finds itself in a state of uncertainty with respect to the dance, and choosing the most successful “dance moves.” This interactive panel will include an in-depth analysis of several mock fact patterns where the parties will address the most pressing challenges still keeping the market up at night, including:  
  • Benefits and risks of taking part in the patent dance
  • What is the minimum requirement necessary to constitute compliance
  • Strategic use of notice of commercial marketing
  • Pros and Cons for biosimilar makers to provide manufacturing information
  • Settlements and potential antitrust concerns